Clinical Trial

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

Study acronym: ACROPOLI
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 21, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-03-15; most recent amendment 2025-03-18.
Status change: Recruiting → Active, Not Recruiting 2025-01-31
Status change: Active, Not Recruiting → Recruiting 2023-07-05
Status change: Recruiting → Active, Not Recruiting 2022-10-24
Status change: Not Yet Recruiting → Recruiting 2021-06-07
Trial Details
NCT Number NCT04802876
Lead Sponsor SOLTI Breast Cancer Research Group
Collaborators: Novartis
Conditions MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma, Mesothelioma, Triple Negative Breast Cancer, Lung Adenocarcinoma, Cholangiocarcinoma, Cervical Carcinoma +23 more
Enrollment 184 participants
Start Date 2021-04-12
Primary Completion 2025-09-30 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-21